IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0785216
(2010-05-21)
|
등록번호 |
US-8597892
(2013-12-03)
|
발명자
/ 주소 |
- Shelton, Jeffrey
- Kelnar, Kevin
- Volz, Stephanie
- Adai, Alex
- Brown, David
|
출원인 / 주소 |
|
대리인 / 주소 |
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
|
인용정보 |
피인용 횟수 :
1 인용 특허 :
1 |
초록
This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing prostate disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as prostate cancer.
대표청구항
▼
1. A method for characterizing whether a prostate disease in a patient is prostate cancer or benign prostatic hyperplasia (BPH), comprising the steps of: a. reverse transcribing a first miRNA and in a serum sample;b. amplifying the first miRNA and the second miRNA;c. measuring the level of the first
1. A method for characterizing whether a prostate disease in a patient is prostate cancer or benign prostatic hyperplasia (BPH), comprising the steps of: a. reverse transcribing a first miRNA and in a serum sample;b. amplifying the first miRNA and the second miRNA;c. measuring the level of the first miRNA and the second miRNA, wherein the first miRNA is miR-125b;d. detecting whether the level of miR-125b is elevated; ande. further detecting whether the level of the second miRNA is elevated or reduced,thereby characterizing the prostate disease in the patient as prostate cancer or BPH. 2. The method of claim 1, wherein the second miRNA is miR-24, miR-1, miR-15a, miR-15b, miR-16, miR-17-5p, miR-18a, miR-18a, miR-19a, miR-20a, miR-20b, miR-22, miR-23a, miR-23b, miR-25, miR-26a, miR-26b, miR-28, miR-29a, miR-29c, miR-30a-5p, miR-30b, miR-30c, miR-30d, miR-30e-3p, miR-32, miR-92, miR-93,miR-98, miR-103, miR-106a, miR-107, miR-125a, miR-126, miR-130a, miR-130b, miR-132, miR-140, miR-142-5p,miR-143,miR-145, miR-148a, miR-155,miR-181c, miR-185, miR-191, miR-192, miR-193a, miR-194, miR-195, miR-196b, miR-197, miR-199a, miR-214, miR-222, miR-223,miR-224, miR-301miR-328, miR-331, miR-335, miR-339, miR-340,miR-342,miR-345, miR-361, miR-365, miR-374, miR-422b, miR-423, miR-425, miR-565, miR-576, miR-584, miR-638, miR-660let-7a let-7d, let-7f, or let-7g. 3. The method of claim 1, wherein the stage of the prostate cancer is characterized based on the level of the first miRNA and the second miRNA. 4. The method of claim 1, wherein the amplification is by quantitative reverse transcriptase polymerase chain reaction. 5. The method of claim 1, wherein the first miRNA is expressed at elevated levels in patients with prostate cancer, and the second miRNA is expressed at reduced levels in patients with prostate cancer. 6. The method of claim 1, wherein the first and the second miRNAs are expressed at elevated levels in patients with prostate cancer. 7. The method of claim 1, wherein the progression of prostate cancer is characterized based on the level of the first miRNA and the second miRNA. 8. The method of claim 1, wherein the aggressiveness of the prostate cancer is evaluated based on the level of the first miRNA and the second miRNA. 9. The method of claim 1, wherein the second miRNA is miR-24.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.